Galena Biopharma PT Raised to $12.00 (GALE)
Equities research analysts at Roth Capital boosted their price objective on shares of Galena Biopharma (NASDAQ:GALE) from $11.00 to $12.00 in a research note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. Roth Capital’s price objective points to a potential upside of 72.41% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group raised their price target on shares of Galena Biopharma from $6.00 to $9.00 in a research note to investors on Wednesday, January 8th. They now have a “buy” rating on the stock. Analysts at Oppenheimer initiated coverage on shares of Galena Biopharma in a research note to investors on Tuesday, November 26th. They set an “outperform” rating and a $6.00 price target on the stock. Six analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $6.29.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.